AstraZeneca Pharma India Limited (NSE: ASTRAZEN) inaugurated its new corporate office in Mumbai, marking a significant step in its growth through innovation. The new office, spanning 25,600 sq ft, was inaugurated by Honorable Shri Devendra Fadnavis, Chief Minister of Maharashtra, alongside senior government officials and dignitaries.

Strategic Expansion

The new office signifies AstraZeneca’s ambition to transform care by unlocking the power of science. The company has introduced over 25 new medicines and indications in India in the past three years and is currently running about 80 global clinical trials in the country. This strategic move presents several opportunities for closer and effective partnerships with a vibrant healthcare ecosystem.

Commitment to Innovation

Arun Krishna, Non-Executive Director on the Board of AstraZeneca Pharma India Limited, emphasized India’s importance to AstraZeneca’s growth across Asia. The new commercial office in Mumbai will support closer engagement with stakeholders and the continued development of the company’s people. This step also supports AstraZeneca’s continued investment in talent and capability building in India, creating opportunities for professionals passionate about transforming healthcare.

As AstraZeneca expands, it will seek to attract and develop diverse talent across the value chain, reinforcing its broader purpose of advancing equitable healthcare globally. With this, India becomes one of the largest and diverse footprints of the organization around the world, supporting commercial operations, site management and monitoring, technology, research and development, and global business services.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

AstraZeneca drops 25.6% over three months and trades near its 52-week lows. The PEG reaches 3.73. The stock trades on brand and index weight, not on growth. Thin margins at 7.0% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Sellers drive 1.6x the volume of buyers. Furthermore, they controlled 18 of recent sessions versus 12 for buyers — a clear distribution signal. The business compounds at 31.3% revenue and 23.6% profit CAGR, with D/E of 0.00. Yet the stock drops 25.6% in three months. The business does not deteriorate — the stock does. That gap is what long-term investors look for. Check Fundamentals of AstraZeneca Pharma India Limited.

Solara Active Pharma Sciences Limited (SOLARA) has reported a stellar Q2 FY27 performance, with revenue surging 33% year-on-year to INR 4,178 Mn and EBITDA more than doubling to INR 769 Mn, marking its best quarter in five years. The company’s base business, excluding Ibuprofen, saw revenue grow 37% to INR 3,273 Mn and EBITDA jump 68% to INR 771 Mn. The Ibuprofen business, which was previously a loss-making segment, is now close to breakeven with revenue up 21% year-on-year and 18% quarter-on-quarter. The company’s overall profitability has improved significantly, with PAT turning positive at INR 285 Mn, compared to a loss of INR 101 Mn in the same period last year.

Base Business Performance

The base business continues to drive the overall growth, with revenue increasing 37% year-on-year to INR 3,273 Mn and EBITDA growing 68% to INR 771 Mn. The EBITDA margin expanded by 440 basis points year-on-year to 23.6%, reflecting improved business and operational efficiency.

Ibuprofen Business Turnaround

The Ibuprofen business has shown significant improvement, with revenue growing 21% year-on-year and 18% quarter-on-quarter. The EBITDA loss has narrowed to INR 2 Mn from INR 87 Mn in the previous quarter, indicating the business is now close to breakeven.

Overall Financial Health

Overall, Solara Active Pharma Sciences Limited has achieved its highest quarterly EBITDA and PAT in the last five years. Net debt has decreased by INR 1,141 Mn in H1 FY27 to INR 5,000 Mn, and the net debt to EBITDA ratio has improved to 1.8x from 3.2x at the end of FY26, strengthening the company’s balance sheet.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Solara posts a 13.7% three-month gain, but softens in the last few weeks. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue contracts at -1.2% CAGR. That signals structural headwinds, not a short-term blip. The stock gives back 9.4% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock holds up despite -1.2% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Solara Active Pharma Sciences Limited.

Wanbury Limited (WANBURY) has announced significant regulatory milestones and business expansions, reinforcing its position as a leading global supplier of Active Pharmaceutical Ingredients (APIs) and formulations. In July-August 2026, the company received 9 ‘No DMF Deficiency’ letters from the USFDA for its Metformin HCl Drug Master File (DMF), along with similar letters for Paroxetine and Diphenhydramine HCl APIs. These endorsements highlight the quality of Wanbury’s regulatory filings and open new business opportunities in the regulated US market.

Strengthening the API Pipeline

Wanbury is further expanding its API portfolio by validating new products, including Quetiapine Fumarate, Sitagliptin, and Empagliflozin. Regulatory filings for these products are planned for the next quarter, with the APIs expected to be available for sale in semi-regulated markets, adding to the company’s growth avenues.

Global Metformin Business Expansion

Wanbury has also made notable strides in its Metformin business. In Saudi Arabia, the company has commercialised a new Metformin DC (directly compressible) business, with an annual revenue potential of about Rs 10 crore. Additionally, a customer in Mexico has won a two-year tender for the supply of Metformin, valued at approximately Rs 15 crore per annum. These developments underscore Wanbury’s robust growth strategy in the Metformin sector.

Commenting on the developments, Mr. Mohan Rayana, Director of Wanbury Limited, said, “The ‘No DMF Deficiency’ letters from the USFDA are a strong endorsement of our quality and regulatory capabilities. With new Metformin business in Saudi Arabia and Mexico, and new APIs such as Quetiapine Fumarate, Sitagliptin, and Empagliflozin in our pipeline, we are well placed for sustained growth”.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Wanbury Limited

Wanbury Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Wanbury drops 43.9% over three months and trades near its 52-week lows. Thin margins at 8.6% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 27, well into oversold territory. Yet sellers still dominated on 21 of recent sessions versus 9 for buyers, so the pressure has not fully lifted. Revenue grows at 8.9% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Wanbury Limited.